【摘要】：以往30年中針對眾多靶點(diǎn)的阿爾茨海默病(AD)治療藥物的研發(fā),雖然全球藥業(yè)公司、政府、研究機(jī)構(gòu)、大學(xué)和風(fēng)險(xiǎn)投資機(jī)構(gòu)等都投入了大量的人力物力資源,但2003年以來FDA沒有批準(zhǔn)一個(gè)AD藥物上市。究其原因,固然與無法早期診斷、治療策略欠佳及患者的遺傳多態(tài)性帶來藥物反應(yīng)的多樣性等因素有關(guān),更主要的原因可能是對包括AD在內(nèi)的許多復(fù)雜性疾病發(fā)病機(jī)制的了解還很膚淺。繼續(xù)按照目前思路針對單個(gè)靶點(diǎn)的AD藥物研發(fā)可能不是明智的做法。系統(tǒng)生物醫(yī)學(xué)等發(fā)展為認(rèn)知疾病網(wǎng)絡(luò)機(jī)制及基于系統(tǒng)藥理學(xué)的多靶點(diǎn)藥物研發(fā)帶來了希望;建立在深入的基礎(chǔ)研究水平上的神經(jīng)干細(xì)胞移植或小分子藥物影響神經(jīng)干細(xì)胞再生可能成為AD治療的新途徑;生物標(biāo)志物的發(fā)現(xiàn)為研究AD發(fā)病機(jī)制及新型藥物研發(fā)將帶來啟迪。
[Abstract]:Over the past 30 years, many targets have been developed for Alzheimer's disease (AD), although global pharmaceutical companies, governments, research institutions, universities and venture capital firms have invested a lot of human and material resources. But FDA has not approved a AD drug since 2003. The reasons are, of course, related to the lack of early diagnosis, poor treatment strategies and the diversity of drug reactions brought about by genetic polymorphisms in patients. The main reason may be that knowledge of the pathogenesis of many complex diseases, including AD, is superficial. It may not be wise to continue to target individual AD drugs on current thinking. The development of system biomedicine brings hope to the network mechanism of cognitive disease and the research and development of multi-target drugs based on systematic pharmacology. Neural stem cell transplantation or small molecule drugs which are based on the basic research level may be a new way to treat AD. The discovery of biomarkers will enlighten the study of the pathogenesis of AD and the development of new drugs.
【作者單位】： 上海交通大學(xué)藥學(xué)院;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(81270432)
【分類號】：R96;R749.16

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 汪華僑,范海虹,徐杰,李光武,袁群芳,謝瑤,姚志彬;抗氧化劑TA99系列治療阿爾茨海默病的實(shí)驗(yàn)依據(jù)(英文)[J];中國臨床康復(fù);2005年13期

2 錢云;張志s，

本文編號：2342190